Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study - 11/01/24
Doi : 10.1016/j.jaad.2023.09.082
Guihong Wan, PhD a, b, Nga Nguyen, MD, MPH a, Bonnie W. Leung, MD a, Hannah Rashdan, BS a, Kimberly Tang, BA a, Katie Roster, MS a, Michael R. Collier, BS a, Pearl O. Ugwu-Dike, BS a, Neel S. Raval, BA a, Nora A. Alexander, BS a, Ruple Jairath, BS a, Jordan Phillipps, BS a, Munachimso Amadife, BS a, Shijia Zhang, MBI a, Alexander Gusev, PhD c, Steven T. Chen, MD a, Kerry L. Reynolds, MD d, Nicole R. LeBoeuf, MD, MPH e, Shawn G. Kwatra, MD f, Yevgeniy R. Semenov, MD, MA a, b, ⁎ 
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
b Department of Dermatology, Harvard Medical School, Boston, Massachusetts
c Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts
d Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
e Department of Dermatology, Dana Farber Cancer Institute, Boston, Massachusetts
f Department of Dermatology, Johns Hopkins University, Baltimore, Maryland
∗Correspondence to: Yevgeniy R. Semenov, MD, MA, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, 40 Blossom St, Bartlett Hall 6R, Room 626, Boston, MA 02114Department of DermatologyHarvard Medical SchoolMassachusetts General Hospital40 Blossom StBartlett Hall 6RRoom 626BostonMA02114
Key words : autoimmunity, cutaneous adverse reactions, cutaneous immune-related adverse events, immunotherapy, immune checkpoint inhibitor, oncodermatology, pre-existing inflammatory disease
| Drs Wan and Nguyen are co-first authors. |
|
| Drs Kwatra and Semenov are co-senior authors. |
|
| Funding sources: YRS is supported in part by the Department of Defense under Award Number W81XWH2110819, the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23 AR080791, and the Melanoma Research Alliance Young Investigator Award. SGK is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23AR077073. NRL is supported by NIH/NCI grant U54-CA225088. The other authors received no funding for this research. The content is solely the responsibility of the authors and does not represent the official views of the funders. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Reviewed and approved by Mass General Brigham Institutional Review Board (Protocol # 2020P002307). |
© 2023
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 90 - N° 2
P. 418-420 - febbraio 2024 Ritorno al numero
Articolo precedente
- Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
- Alexander J. Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Karl D. Lewis, Nicole Basset-Seguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Suk-Young Yoo, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Timothy J. Inocencio, Chieh-I Chen, Patrick R. LaFontaine, Frank Seebach, Israel Lowy, Matthew G. Fury
- Research letter: BRAF-inhibitor induced panniculitis - A systematic review
- Yae Kye, Grant Zhao, Samantha Guhan, Denise Nunes, Cuong V. Nguyen
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?